Метод оценки доз излучения инкорпорированных радиофармацевтических препаратов терапевтического и диагностического назначения с использованием стандартных фантомов человека
Диссертация
Однако многие опухолевые заболевания, в том числе и костные метастазы рака щитовидной железы обладают высокой резистентностью к 7- и-излучениям, что во многом объясняется недостаточной эффективностью лечения этих метастазов при использовании изотонического раствора 1311. В связи с этим, одним из перспективных направлений в радионуклидной терапии стала работа с а-эмиттерными РФП, которые обладают… Читать ещё >
Содержание
- Глава 1. Альфа-эмиттеры и их роль в радионуклидной терапии
- Глава 2. Метод оценки доз внутреннего облучения с использованием стандартных фантомов человека
- Глава 3. Оценка поглощенных доз в полых органах человека для РФП с высокой долей а- и ff-излучения
- Глава 4. Метод оценки поглощенных доз для кости и красного костного мозга в рамках «костной модели»
Глава 5. Прогноз доз облучения для человека по данным биологических испытаний в случае радиофармпрепарата «Астат — 211» и других, отечественных радиофармпрепаратов терапевтического и диагностического назначения.
ОСНОВНЫЕ РЕЗУЛЬТА ТЫ И
ВЫВОДЫ.
Список литературы
- Macklis R. M,. Lin J.Y., Beresford В., Atcher R.W., Hines J J., Humm J.L., Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. //Radial. Res. 1992, v. 130, p.220−226.
- Rotmensch J., Atcher R.W., Schlenker R. The effect of alpha-emitting radionuclide lead 212 on human ovarian carcinoma: a potential new form of therapy. //Gynecol. Oncol. 1989, v.32, p.236−239.
- Carrasquillo J.A., White J.D., Paik C.H. Similarities and differences in 11'in and 90Y-labeled 1B4M-DTPA anti Tac monoclonal antibody distribution. //J. Nucl.Med. 1999, v.40, p.268−276.
- Carrasquillo J.A. Radioimmunotherapy of leukemia and lymphoma. In: Wagner. H. //Principles of Nuclear Medicine. 1996, v.2, p. l 117−1132.
- Larson S.M., Macapinlac H.A., Scott A.M., Divgi C.R. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. //Acta Oncol. 1993, v.32, p.709−715.
- Bigler R.E., Zanzonico P.B., Cosma M., Sgouros G. Adjuvant radioimmunotherapy for micrometastases: a strategy for cancer cure. //Plenum Press. 1988, p.409−429.
- Andersson H., Lindegren S., Back T. Radioimmunotherapy of nude• 01 1 mice with intraperitoneal^ growing ovarian cancer xenograft utilizing Atlabelled monoclonal antibody MOvl8. //Anticancer Res. 2000, v.20, p.459−462.
- Andersson H., Lindegren S., Back T. The curative and palliative potential of the monoclonal antibody MOvl8 labelled with 21'At in nude micewith intraperitoneally growing ovarian cancer xenografts: a long term study. //Acta Oncol. 2000, v.39, p.741−745.
- Jurcic J.G., Larson S.M., Sgouros G. Targeted a-particle immunotherapy for myeloid leukemia. //Blood. 2002, v. 100, p. 1233−1239.
- Sautter-Bihl M.L., Herbold G., Bihl H. Minimal residual disease: a target for radioimmunotherapy with 13lI-labeled monoclonal antibodies. Some dosimetric considerations. //Recent Results Cancer Res. 1996, v. 141, p.67−75.
- Zalutsky M.R., Cokgor I., Akabani G. Phase I trial of alpha-particle-emitting astatine-211. labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients. //Pro.c Am. Assoc. Cancer Res. 2000, v.41, p.544.
- Sharkey R.M., Sausville E.A., Goldenberg D.M. Meeting Report on the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates. //Cancer Research. 2003, v.63, p.8069−8071.
- H. Lee Moffitt. Radioimmunotherapy With alpha-Particle Emitters. //Cancer Control. 2002, v.9,№ 2, p. 106−113.----------- ------15. Andersson H., Elgqvist J., Horvath G., Hultborn R., Jacobsson L.,
- Jensen H., Karlsson В., Lindegren S., Palm S. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. //Clinical Cancer Research. 2003, v.9, p.3914−3921.
- Back Т., Andersson H., Divgi C.R., Hultborn R., Jensen H., Lindegren2|i e л
- S., Palm S., Jacobsson L. At Radioimmunotherapy of Subcutaneous Human Ovarian Cancer Xenografts: Evaluation of Relative Biologic Effectiveness of an «-Emitter In Vivo. //J. Nucl. Med. 2005, v. 46, p.2061−2067.
- McDevitt M.R., Sgouros G., Finn R.D., Humm J.L., Jurcic J.G., Larson S.M., Scheinberg D.A. Radioimmunotherapy with o-emitting nuclides. //Eur. J. Nucl. Med. 1998, v.25, p. 1341−1351.
- Jamal Zweit. Radionuclides and carrier molecules for therapy. //Phys. Med. Biol. 1996, p.1905−1914.
- Vaidyanathan G., Zalutsky M.R. Targeted therapy using alpha emitters. //Phys. Med. Biol. 1996, v.41, p. 1915−1931.
- Zalutsky M.R., Schuster J.M., Garg P.K., Archer G.E., Dewhirst M.W., Bigner D.D. Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. //Recent Results Cancer Res. 1996, v. 141, p. 101−22.
- Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. //Acta Oncol. 1996, v.35, p.373−379.
- Comparative Cellular Catabolism and Retention of Astatine-, Bismuth-, and Lead-Radiolabeled Internalizing Monoclonal Antibody //J. Nucl. Med. 2001, v.42, p.1538−1544.
- Схемы распада радионуклидов. Энергия и интенсивность излучения. Рекомендации МКРЗ, публикация 38'- В 3 томах, ред. Моисеев, А.А.- М.: Энергоатомиздат, 1987,100 с.
- Bloomer W.D., McLaughlin W.H., Neirinckx R.D. Astatine-211— tellurium radiocolloid cures experimental malignant ascites. //Science. 1981, v.212, p.340−341.
- Brown I., Mitchell J.S. The development of a 2UAt.-astatinated endoradiotherapeutic drug. IV. Late radiation effects. //Int J Radiat Oncol Biol Phys. 1998, v.40,p.l 177−1183.
- Link EM. Targeting melanoma with 2llAt/131I-methylene blue: preclinical and clinical experience. //Hybridoma. 1999, v.18, p.77−82.
- Vaidyanathan G, Zalutsky MR. Meta- Atjastatobenzylguanidine: synthesis via astatodemetallation and preliminary in vitro and in vivo evaluation. //Bioconjugate Chemistry. 1992, v.3, p.499−503.
- Vaidyanathan G., Larsen R.H., Zalutsky M.R. 5−211At.Astato-29-deoxyuridine, an alpha-particle emitting endoradiotherapeutic agent undergoing DNA incorporation. //Cancer Res. 1996, v.56, p. 1204−1209.
- Foulon C.F., Alston K.L., Zalutsky M.R. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. //Nucl Med Biol. 1998, v.25, p.81−88.
- Murud K.M., Larsen R.H., Bruland O.S., Hoff P. Influence ofpretreatment with 3-amino-l-hydroxypropylidene-l, l-bisphosphonate (APB) on 2j 1 1organ uptake of At and I-labeled amidobisphosphonates in mice. //Nucl Med Biol. 1999, v.26, p. 791−794.
- Larsen H.R., Murud K.M., Akabani G., Hoff P., Bruland O.S., Zalutsky M.R.21'At- and, 3II-Labeled Bisphosphonates with High In Vivo-------Stability and Bone Accumulation. //J. Nucl. Med. 1999, v.40, p. l 197−1203.
- Wilbur D.S., Vessella R.L., Stray J.E., Goffe D.K., Blouke K.A., 1. Л 1 1
- Atcher R.W. Preparation and evaluation of para- At. astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F (ab9)2: in vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F (ab9)2. //Nucl Med Biol. 1993, v.20, p.917−927.
- Larsen RH, Bruland OS. Intratumour injection of immunoglobulins labeled with the alpha-particle emitter At: analyses of tumour retention, microdistribution and growth delay. //Br J Cancer. 1998, v.77, p. l 115−1122.
- Zalutsky M.R., Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. //Current Pharmaceutical Design. 2000, v.6, p.1433−1455.
- Humm J.L. Dosimetric Aspects of Radiolabeled Antibodies for Tumor Therapy. //J. Nucl. Med. 1986, v.27, p. 1490−1497.
- Humm JL. A microdosimetric model os As-211-labeled antibodies for radioimmunotherapy. //Int J Radiat Oncol Biol Phys. 1987, v.13, p. l 767−73.
- Hall E.J. Radiobiology for the radiologist. 4th edition, J.B. Lippincott, Philadelphia, 1994, 558 p.
- Ю.Б. Кудряшев. Радиационная биофизика (ионизирующие излучения). ФИЗМАТЛИТ. 2004,448с.
- Mulford D.A., Scheinberg D.A., Jurcic J.G. The Promise of Targeted a-Particle Therapy.//J. Nucl. Med. 2005, v.46, p. 199−204.
- Kampf G. Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. //Radiobiol. Radiother.(Berl). 1988, v.29, p.631−658.
- Евсеенко Л.В., Куракин A.A., Тултаев A.B., Черняев А. П. Математическая, модель фантома человека в радионуклидной диагностике и терапии. Препринт НИИЯФ МГУ 2002−24/708, 63 с.
- Physical models and dose factors for use in internal dose assessment. Stabin M.G., Siegel J.A. //Health Phys. 2003, v.3, p.294−310.
- George Sgouros. Dosimetry of Internal Emitters. //J. Nucl. Med. 2005, v.46, p. 18−27.
- Cristy M., Eckerman K.F. Specific absorbed fractions of energy, at various ages from internal photon sources. ORNL/TM 8381/V/Oak Ridge, 1987,100 p.49. Snyder W., Ford M., Warner G., Fisher H. MIRD Pamphlet No 5
- Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. //J Nucl Med. 1969, v.3, p.7−52.
- Snyder W., Ford M., Warner G., Watson S. MIRD Pamphlet No. 11 -MS» Absorbed dose per unit cumulated activity for selected radionuclides and organs. //Society of Nuclear Medicine. 1975,97p.
- Bouchet L., Bolch W., Weber D., Atkins H., Poston J. MIRD Pamphlet No 15: Radionuclide S values in a revised dosimetric model of the adult head and brain. //J Nucl. Med. 1999, v.40, p.62−101.
- Watson E.E., Stabin M.G., Davis J.L., Eckerman K.F. A model of the peritoneal cavity for use in internal dosimetry. //J Nucl Med. 1989, v.30, p.2002−2011.
- Stabin M.G. A Model of the Prostate Gland for Use in Internal Dosimetry. //J. Nucl. Med. 1994, v.35, p.516−520.
- Bouchet L.G., Bolch W.E., Howell R. W, Rao D.V. S Values for Radionuclides Localized Within the Skeleton. //J. Nucl. Med. 2000, v.41, p.189−212.
- Eckerman K.F., Leggett R.W., Cristy M. Dosimetry concepts for bone-seeking radionuclides, book chapter, in Health Physics Summer School Proceedings- 1984, 40 p.
- Eckerman K.F., Stabin M.G. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. //Health Phys. 2000, v.78, p.199−214.
- Stabin M.G., Eckerman K.F., Bolch W.E., Bouchet L.G., Patton P.W. Evolution and status of bone and marrow dose models. //Cancer Biotherapy and Radiopharmaceuticals. 2002, v.4, p.427−434.
- Wymer D. Intercalibration of In Vivo Counting Systems Using an Asian Phantom. ISBN 92−0-100 403−6,2003,132 p.
- П.В. Горбунов, Д. О. Еременко, С. Ю. Платонов, А. В Тултаев, О. В Фотина, О. А. Юминов. Оценка доз внутреннего облучения костных тканей и красного костного мозга. //Известия РАН, серия физическая. 2006, т.70, № 11, с. 1639−1644.
- M.G. Stabin. Radiotherapy with internal emitters: what can dosimetrists offer?. //Cancer Biother Radiopharm. 2003, v.4, p.611−617
- Нормы радиационной безопасности (НРБ-99) // СП 2.6.1 758−99, Минздрав России. Апрохим, 2000, 109 с.
- Stabin MG, Konijnenberg М. Re-evaluation of absorbed fractions forphotons and electrons in small spheres. //J Nucl Med. 2000, v.41, p. 149−160.
- C.W. Mays. Beta dosimetry in trabecular bone. Delayed effects of bone-seeking radionuclides. //Salt Lake City: Univ. Utah Press. 1969, p. 95−108.
- M.G. Stabin, K. F. Eckerman, W. E. Bolch, L. G. Bouchet, and P. W. Patton. Evolution and status of bone and marrow dose models. //Cancer Biotherapy and Radiopharmaceuticals. 2002, v.17, № 4, p.427−433.
- A.V. Tultaev., O.V. Fotina, O.A. Yuminov, P.V. Gorbunov, D.O.
- Eremenko, S.Yu.Platonov. «Radiation absorbed dose estimates for intravenously 211injected At in thyroid cancer radionuclide therapy». //Book of abstracts: Sixth
- Link E.M., Carpenter R.N., Hansen G. 211At.Methylene Blue for Targeted Radiotherapy of Human Melanoma Xenografts: Dose Fractionation in the Treatment of Cutaneous Tumours. //European Journal of Cancer. 1996, v.7, p.1240−1247.
- Link E.M., Michalowski A.S., Rosch F. 2I1At-methylone blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage. //Pigment Cell Res. 1994, v.5, p.358−362.
- Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. //Cancer Res. 1994, v.17, p.4719−4725.1. Oil
- Brown I., Carpenter R.N. Endogenous At alpha-particle radiotherapy for undifferentiated thyroid cancer. //Acta Radiol Suppl. 1991, v.376, p. 174−175.
- Effects of thyroxine and KSCN on capacity of rat thyroid gland to accumulate astatine-211. Shellabarger C.J., Durbin P. W, Parrott M.W., Hamilton J.G. //Proc Soc Exp Biol Med. 1954, v.3, p.626−629.
- Garg P.K., Harrison C.L., Zalutsky M.R. Comparative tissue• #911 1^1distribution in mice of the alpha-emitter *MAt and 1J, I as labels of a monoclonal antibody and F (ab')2 fragment.53. //Cancer Res. 1990, v.12, p.3514−3520.• Oil
- Preparation and preliminary evaluation of 4- At. astato-N-piperidinoethyl benzamide. Garg P.K., John C.S., Zalutsky M.R. Nucl Med Biol. 1995, v.4, p.467−473.
- Hamilton JG., Durbin PW, Parrott MW. Accumulation of astatine-211 by thyroid gland in man. //Proc Soc Exp Biol Med. 1954, v.2, p.366−369.
- Durbin P.W., Parrott M.W., Hamilton J.G. The accumulation and destructive action of astatine 211 (eka-iodine) in the thyroid gland of rats and monkeys. //J Clin Endocrinol Metab. 1954, v. 10, p. l 161−1178.